-
10:09:03 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

VRCA Stock News

05/27/22 3:27 PM
Nasdaq : VRCA
low float
Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Verrica Pharmaceuticals Inc. (VRCA) Investors
The law firm of Kirby McInerney LLP is investigating potential claims against Verrica Pharmaceuticals Inc.. If you purchased or otherwise acquired Verrica securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this...
RHEA-AI
very negative
05/24/22 8:00 PM
Nasdaq : VRCA
low float
Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC
Verrica has been advised that PAI (Pre-Approval Inspection) was conducted at Sterling and is not aware of any reported observations related to the PAI of VP-102 operations Review Division had advised Verrica that the review of NDA was completed and label was ready to be communicated, except for
RHEA-AI
neutral
04/05/22 7:30 AM
Nasdaq : VRCA
clinical triallow float
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
LTX-315’s novel mechanism of action directly targets cancerous skin cells to induce an anti-tumor immune response, providing a potential alternative to surgery There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need for new treatment
RHEA-AI
neutral